Literature DB >> 20820979

RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis.

Juwon Park1, Eunkyung Bae, Chansu Lee, Sung-Soo Yoon, Yang Seok Chae, Kwang-Sung Ahn, Nam Hee Won.   

Abstract

Human renal cell carcinoma (HRCC) is characterized by a high level of resistance to all treatment modalities. Therefore, the investigation of global gene expression in HRCC might help understand its biologic behavior and develop treatment strategies. Using cDNA microarray analysis, we initially compared gene expression profiles between HRCCs and adjacent normal tissues, and found that 87 were up-regulated and 127 genes were down-regulated. Next, a subset of genes, twofold differentially expressed, were validated by Northern blotting. Unexpectedly, caveolin-1, a gene reported to be a tumor suppressor gene, was found to be up-regulated in HRCC tissues. Expression level of caveolin-1 in SN12CPM6 (high metastatic clone) was higher than in SN12C (low metastatic clone), and SN12CPM6 was more resistant to doxorubicin (DXR) than SN12C. Caveolin-1 gene was slightly induced in surviving SN12C cells after DXR treatment. Furthermore, SN12CPM6-siCav1 cells, which were transfected with siRNA of cavelon-1 gene, were more sensitive to DXR, compared to SN12CPM6, but reduction of caveolin-1 gene expression did not affect tumor formation in subcapsule of kidney and lung metastasis. On the other hand, induction of caveolin-1 gene affected the production of lung metastasis under anti-cancer drug treatment: the incidence of pulmonary metastasis was significantly lower in SCID mice injected with SN12CPM6-siCav1 cells, and the number of pulmonary nodules decreased significantly (p = 0.0004). The above results together suggest that caveolin-1 may confer a growth advantage to cancer cells during DXR chemotherapy and surviving HRCC cells eventually might develop lung metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20820979     DOI: 10.1007/s13277-010-0081-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  Morphological adjustment of senescent cells by modulating caveolin-1 status.

Authors:  Kyung A Cho; Sung Jin Ryu; Yoon Sin Oh; Ji Hyeun Park; Jung Weon Lee; Hwang-Phill Kim; Kyung Tae Kim; Ik Soon Jang; Sang Chul Park
Journal:  J Biol Chem       Date:  2004-07-19       Impact factor: 5.157

Review 2.  Caveolae and caveolins.

Authors:  R G Parton
Journal:  Curr Opin Cell Biol       Date:  1996-08       Impact factor: 8.382

3.  Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells.

Authors:  Martin M Bélanger; Elise Roussel; Jacques Couet
Journal:  Anticancer Drugs       Date:  2003-04       Impact factor: 2.248

4.  Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells.

Authors:  W Y Park; J S Park; K A Cho; D I Kim; Y G Ko; J S Seo; S C Park
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

5.  Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells.

Authors:  L Li; G Yang; S Ebara; T Satoh; Y Nasu; T L Timme; C Ren; J Wang; S A Tahir; T C Thompson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

6.  Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells.

Authors:  S W Lee; C L Reimer; P Oh; D B Campbell; J E Schnitzer
Journal:  Oncogene       Date:  1998-03       Impact factor: 9.867

7.  CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines.

Authors:  Eliska Thorburn; Libor Kolesar; Eva Brabcova; Katerina Petrickova; Miroslav Petricek; Marcela Jaresova; Antonij Slavcev; Ilja Striz
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

8.  A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage.

Authors:  Jens Bedke; Peter J Nelson; Eva Kiss; Niklas Muenchmeier; Angelika Rek; Carl-Ludwig Behnes; Norbert Gretz; Andreas J Kungl; Hermann-Josef Gröne
Journal:  Mol Immunol       Date:  2009-12-11       Impact factor: 4.407

9.  Transforming growth factor-beta as a treatment target in renal diseases.

Authors:  Noboru Fukuda; Yoshiko Tahira; Hiroyuki Matsuda; Koichi Matsumoto
Journal:  J Nephrol       Date:  2009 Nov-Dec       Impact factor: 3.902

10.  Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.

Authors:  G H Mickisch; K Roehrich; J Koessig; S Forster; R K Tschada; P M Alken
Journal:  J Urol       Date:  1990-09       Impact factor: 7.450

View more
  13 in total

1.  Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance.

Authors:  Stephanie Hehlgans; Nils Cordes
Journal:  Am J Cancer Res       Date:  2011-03-20       Impact factor: 6.166

2.  Caveolin-1 regulates cell apoptosis and invasion ability in paclitaxel-induced multidrug-resistant A549 lung cancer cells.

Authors:  Fei Han; Long Zhang; Yongxin Zhou; Xianghua Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.

Authors:  Ye Zhang; Xiujuan Qu; Ce Li; Yibo Fan; Xiaofang Che; Ximing Wang; Ying Cai; Xuejun Hu; Yunpeng Liu
Journal:  Tumour Biol       Date:  2014-11-19

4.  Volatile anesthetics protect cancer cells against tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via caveolins.

Authors:  Yoshitaka Kawaraguchi; Yousuke T Horikawa; Anne N Murphy; Fiona Murray; Atsushi Miyanohara; Sameh S Ali; Brian P Head; Piyush M Patel; David M Roth; Hemal H Patel
Journal:  Anesthesiology       Date:  2011-09       Impact factor: 7.892

5.  Caveolin-1 sensitizes cisplatin-induced lung cancer cell apoptosis via superoxide anion-dependent mechanism.

Authors:  Kanittha Pongjit; Pithi Chanvorachote
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

6.  Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.

Authors:  Lee Campbell; Ghaith Al-Jayyoussi; Robert Gutteridge; Nigel Gumbleton; Rosie Griffiths; Simon Gumbleton; Mathew W Smith; David F R Griffiths; Mark Gumbleton
Journal:  J Transl Med       Date:  2013-10-11       Impact factor: 5.531

Review 7.  Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer.

Authors:  Ismael Riquelme; Pablo Letelier; Angela L Riffo-Campos; Priscilla Brebi; Juan Carlos Roa
Journal:  Int J Mol Sci       Date:  2016-03-22       Impact factor: 5.923

Review 8.  Versatile Functions of Caveolin-1 in Aging-related Diseases.

Authors:  Kim Cuc Thi Nguyen; Kyung A Cho
Journal:  Chonnam Med J       Date:  2017-01-25

9.  Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.

Authors:  Kevin Quann; Donna M Gonzales; Isabelle Mercier; Chenguang Wang; Federica Sotgia; Richard G Pestell; Michael P Lisanti; Jean-François Jasmin
Journal:  Cell Cycle       Date:  2013-04-17       Impact factor: 4.534

Review 10.  Caveolin-1 as a promoter of tumour spreading: when, how, where and why.

Authors:  Rebecca Senetta; Giulia Stella; Ernesto Pozzi; Niccolo Sturli; Daniela Massi; Paola Cassoni
Journal:  J Cell Mol Med       Date:  2013-03-23       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.